Watching Adial Pharmaceuticals; Brookline Capital Markets Says 'We Believe The Announcement Of A New Patent Issuance Increases The Potential For Partners To Engage With The Company' Reiterates Buy And $26 Price Target"
Watching Adial Pharmaceuticals; Brookline Capital Markets Says 'We Believe The Announcement Of A New Patent Issuance Increases The Potential For Partners To Engage With The Company' Reiterates Buy And $26 Price Target"
關注Adial Pharmicals;布魯克林資本市場表示 “我們相信新專利的發佈增加了合作伙伴與公司合作的可能性” 重申了買入和26美元的目標股價”
Watching Adial Pharmaceuticals; Brookline Capital Markets Says 'We Believe The Announcement Of A New Patent Issuance Increases The Potential For Partners To Engage With The Company' Reiterates Buy And $26 Price Target"
關注Adial Pharmicals;布魯克林資本市場表示 “我們相信新專利的發佈增加了合作伙伴與公司合作的可能性” 重申了買入和26美元的目標股價”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。